Summary

  • Centrus’s priced packages add to $500,000,064.02 before discounts and expenses, but only 500,000 common shares are sold outright; 2,005,513 near-share equivalents sit in immediately exercisable pre-funded warrants with $0.10 left to pay.
  • Four common-warrant series cover up to 6,992,382 additional shares at strikes from $226.8625 to $362.9800. Their roughly $2 billion aggregate cash-exercise value is an option ceiling, not proceeds already raised or dilution already incurred.

The neatest number in Centrus Energy Corp.’s September financing is not the one that matters most. Multiply 500,000 common shares by the $199.64 package price and the result is $99.82 million. Multiply 2,005,513 pre-funded warrants by $199.54 and the result is $400,180,064.02. Together they produce $500,000,064.02, which is why the issuer reasonably calls the initial gross proceeds approximately $500 million.

That arithmetic settles the first clock. It does not settle the capital structure.

The buyers also received a pro-rata allocation of common warrants, for no separate public offering price, covering as many as 6,992,382 more Class A shares. Centrus divided those instruments into four series. Their exercise prices are $226.8625, $272.2350, $317.6075 and $362.9800. Each series represents approximately $500 million of aggregate exercise value. If every warrant were ultimately exercised in cash, the four series could therefore bring in about $2 billion beyond the initial sale.

“Could” is doing the financial work. The future amount is neither committed capital nor part of the September cheque. It depends on Centrus’s share price, a holder’s willingness and ability to exercise, registration availability, beneficial-ownership limits, the permitted exercise method and time. A warrant can be exercisable and still expire unused.

The almost-share layer

Pre-funded warrants deserve their own column. A buyer paid $199.54 for each instrument and owes only $0.10 to turn it into one Class A share. Exercising all 2,005,513 in cash would add just $200,551.30 to Centrus’s treasury. Economically, that layer sits much closer to present equity than to an option struck hundreds of dollars above zero. Legally, however, an underlying share is not outstanding merely because most of its purchase price has been paid.

The distinction is especially relevant to denominator work. The preliminary prospectus reported 19,233,908 Class A shares outstanding immediately before the offering. The 500,000 shares sold outright plus the 2,005,513 pre-funded underlying shares equal 2,505,513, or 13.03% of that static starting count. It is a useful sensitivity measure, not a prediction of any investor’s ownership: the pre-funded instruments carry blockers, future share counts can change and exercise timing belongs to holders.

Those blockers also explain one reason issuers use the form. The preliminary prospectus starts a holder’s exercise limit at 4.99% beneficial ownership. A holder may raise it with notice, but not above 9.99%. Capital can be paid in without requiring all corresponding shares to appear in the legal outstanding count at once.

Four prices, eight windows

The common warrants create a different map. Series A represents roughly 2.204 million shares at $226.8625. Series B represents roughly 1.837 million at $272.2350. Series C represents roughly 1.574 million at $317.6075. Series D represents roughly 1.377 million at $362.9800. Those are approximations derived from the issuer’s statement that each series carries about $500 million of aggregate exercise value; the issuer’s controlling total is up to 6,992,382 shares.

Every series is split in half. The first tranche expires on September 10 of 2028, 2029, 2030 or 2031, depending on the series. The second expires nine weeks later, on November 12 of the same year. This is not a vesting ladder. Investors received immediately exercisable instruments. It is a price-and-time ladder: two final decision windows at each of four strikes.

The second window matters when a share price is hovering around a strike or when a holder needs more time to arrange capital. It also prevents one date from carrying the entire expiry effect. But nine weeks is not protection against a weak underlying price. If the stock remains below a strike, more calendar does not create intrinsic value.

The warrants are not intended for listing on a national securities exchange. That means quoted liquidity should not be assumed. Holders may transfer the instruments subject to their terms, but an immediately exercisable warrant without an established public market is not equivalent to a freely traded share.

Cash proceeds and shares do not have to arrive together

The preliminary prospectus adds a less obvious control. When the registration statement for underlying shares is unavailable, a holder can use a formula-based cashless exercise. Separately, on each six-month anniversary after issuance and with at least 15 days’ notice, Centrus may elect an irrevocable six-month period during which the common warrants may be exercised only cashlessly.

That election is a method switch, not a call right. It does not compel a holder to exercise and does not allow Centrus to summon $500 million from a series. In a cash exercise, the company receives the strike price and issues the contracted shares. In a cashless exercise, the holder receives a smaller net number of shares based on the value above the strike, and Centrus does not receive the equivalent exercise cash.

The result is a trade-off inside the option. Cash exercise maximises funding if holders choose to act, but issues the full exercise share count. Cashless exercise reduces the number of shares delivered for a given in-the-money warrant, but forgoes the cheque. The issuer can periodically constrain the method; the market still controls whether the warrant has value and the holder still controls whether to exercise.

This is why adding the initial $500 million and the four $500 million series into a $2.5 billion “raise” would be wrong. The first amount is priced purchase consideration, subject to closing conditions and deductions. The next four are contingent exercise values. They can emerge in different years, in part, not at all, or as net shares without corresponding cash.

A large ruler beside a large balance sheet

The maximum-share arithmetic is equally easy to overstate. The 6,992,382 common-warrant shares equal 36.35% of the 19,233,908 pre-offering Class A count. Add the 500,000 sold shares and the 2,005,513 pre-funded underlying, and the total potential increment is 9,497,895, or 49.38% of that static denominator.

Those percentages are stress rulers. They are not a fully diluted forecast. Cashless netting could reduce issuance. Warrants can expire. Ownership blockers can delay exercise. Centrus can issue or repurchase other shares. The relevant denominator in 2031 will not necessarily resemble the one in September 2026.

Nor does the financing begin from an empty treasury. Centrus reported $1.8685 billion of cash and cash equivalents and $1.8876 billion of working capital at June 30. Its long-term debt carrying value was $1.1775 billion, against $1.2075 billion of principal on notes due in 2030 and 2032. First-half capital expenditure was $94.8 million, far above $5.7 million a year earlier, while operating activities used $16.7 million.

That backdrop changes the question from survival funding to allocation. The stated uses are broad: working capital, technology development and deployment, debt repayment or repurchase, capital spending, acquisitions and other opportunities. The preliminary prospectus also noted advanced discussions over a possible domestic manufacturing-supplier acquisition expected to cost $115 million to $125 million, but no definitive agreement. That possibility illustrates optionality; it does not earmark the offering.

Centrus sits inside a capital-intensive attempt to expand domestic uranium-enrichment capacity while import restrictions and geopolitical exposure complicate supply. More cash can support a longer industrial runway. Yet a wide use-of-proceeds clause also means investors must judge deployment after the financing, not infer it from the size of the cheque.

The pricing announcement, preliminary prospectus and June quarterly report therefore describe a financing with three distinct states: cash paid at closing, equity almost paid for, and future options whose price, date and method remain open. Treating them separately is less dramatic than one giant fully diluted figure. It is also more accurate.